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radiographic score (mean joint score of 474-10.4 vs. 20.264-8.2). 
RF and anti- CCP antibodies were absent in all patients. There 
was a trend for higher CRP in cases (mean level of 0.905 mg/dl 
4- 1.35) compared to controls (mean level of 0.272 mg/d14-0.22). 
Of significance, there was a correlation of CRP with higher radio- 
graphic score (p of 0.071). Sera from 10 patients was evaluated 
for COME There was no difference in levels between cases and 
controls (cases 11.1 U/L4-4.13, controls 12.36U/L4- 1.38). 
Conclusion: Erosive hand OA may represent a distinct subset 
of OA. In spite of significant erosive disease in these individuals, 
both RF and anti- CCP antibodies were negative, corroborating 
recent findings. Further evaluation of COMP in this population, 
particularly accounting for the overall burden of OA, is warranted. 
The trend towards elevated CRP in the erosive hand OA suggests 
that this may represent a systemic inflammatory disorder. 
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Aim of the study: To determine Coil 2-1 level, a peptide of type II 
collagen triple helix, and its nitrated form (Coil 2-1 NO2) in serum 
of patients with knee or hip osteoarthritis (OA) before and three 
months after knee or hip replacement. 
Methods: Coil 2-1 and Coil 2-1 NO2 were measured by two 
specific competitive immunoassays in 35 healthy subjects and 
in 44 patients with knee or hip OA candidates for joint re- 
placement. Sera were taken the day before the surgery and 
three months after the hip or knee replacement. The immunoas- 
says were specific for a peptide of the helical region of type 
II collagen, l°SHRGYPGLDG116 (Coil 2-1), and its nitrated form 
1°SHRGY(NO2)PGLDG116 (Coil 2-1 NO2), respectively. 
Results: Before surgery, Coil 2-1 and Coil 2-1 NO2 levels were 
higher in serum of OA patients than in healthy subjects of the 
same range of age [Coil 2-1:175.30 4- 11.10 nM vs 133.11 4- 7.86 
nM (p<0.01) and Coil 2-1 NO2:0.94 4- 0.09 nM vs 0.49 4- 0.03 
nM (p< 0.001)]. Three months after hip or knee replacement, Coil 
2-1 concentration in serum of OA patients decreased below the 
level of the healthy subjects [86.99 4- 5.36 nM vs 133.11 4- 7.86 
nM (p<0.001)]. Moreover, a significant correlation between Coil 
2-1 levels in OA patients before and after hip or knee replacement 
has been found (r = 0.43, p=0.009). In contrast, Coil 2-1 NO2 
serum level did not vary after surgery (0.75 4- 0.05 nM). 
Conclusions: These findings suggest that Coil 2-1 and Coil 2- 
1 NO2 are interesting markers for detection of late structural 
change in OA patients. Furthermore, the decrease of Coil 2-1 
after surgery and the correlation between pre- and post-surgery 
serum levels of Coil 2-1 suggest that Coil 2-1 is a disease-specific 
marker. 
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Aim of Study: A major and early feature of cartilage degenera- 
tion is proteoglycan breakdown. MMP-13 plays an important role 
in osteoarthritic (OA) cartilage degradation. This MMP, in addition 
to initiating collagen fiber cleavage, also acts on several proteo- 
glycans. Among the proteoglycan families, one termed the small 
leucine-rich proteoglycans (SLRPs) was found to be involved in 
collagen fibril formation/interaction, with some members demon- 
strating a role in the OA process. We investigated the ability of 
MMP-13 to cleave members of two classes of SLRPs: 1) bigly- 
can and decorin and 2) fibromodulin and lumican. 
Methods: SLRPs were isolated from human normal and OA car- 
tilage using guanidinium chloride (4 M) extraction. Digestion prod- 
ucts were examined by Western blotting. The identity of the MMP- 
13 degradation products of biglycan (using specific substrate) 
was determined following electrophoresis and microsequencing. 
Results: We showed that the SLRPs studied were cleaved to dif- 
fering extents by human MMP-13. Although only minimal cleav- 
age of decorin and lumican was observed, cleavage of fibromod- 
ulin and biglycan was extensive, suggesting that both molecules 
are preferential substrates. In contrast to decorin, and lumican, 
which yielded a similar degradation pattern for both normal and 
OA, biglycan, but particularly fibromodulin, had a higher level of 
degradation with increased cartilage damage. Microsequencing 
revealed a novel major cleavage site (... VPK178-179VFS) for 
biglycan upon exposure to MMP-13. 
Conclusion: We showed, for the first time, the ability of MMP-13 
to degrade members from two classes of the SLRP family, and 
the site at which biglycan is cleaved by MMP-13. The MMP-13- 
induced SLRP degradation may represent an early critical event, 
which may in turn affect the collagen network by the exposure 
of the MMP-13 cleavage site in this macromolecule. Awareness 
of the SLRP degradation products, especially those of biglycan 
and fibromodulin, may assist in early detection of OA cartilage 
degradation. 
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Aim: Chondrocyte hypertrophy, a mediator of OA progression, is 
associated with an upregulation of the transglutaminases FXlIIA 
and transglutaminase 2 (TG2), so we examined the potential role 
of FXlIIA in promoting hypertrophy, an activity recently demon- 
strated for TG2. 
Methods: We employed RNAi knockdown of FXIIIA and TG2 
in cultured normal human knee articular chondrocytes. Primary 
knee chondrocytes also were isolated from TG2 +/+ and TG2- 
/- mice. Recombinant wild type FXlIIA and point mutants were 
generated to examine the need for the defined thrombin activa- 
tion and inactivation endoproteolytic sites, the transamidation cat- 
alytic site, the cation binding site, the isomerization site and the 
calcium binding domain. Bovine articular cartilage explants also 
were treated with recombinant TG2 and FXlIIA for examination of 
type X collagen expression. Finally, human articular chondrocytes 
were transfected and stimulated with recombinant TG2 and FXl- 
IIA to determine xtracellular TG2 levels by ELISA, expression of 
type X collagen and phosphorylation of p38 MAPK. 
Results: Recombinant wild type FXlIIA (100 ng/ml) induced 
chondrocyte hypertrophy, an activity dependent on both TG2 ex- 
pression and of TG2 externalization, as confirmed using TG2 -/- 
knee chondrocytes. FXlIIA did not act by directly binding or chap- 
